Alexa Fluor® 488 Anti-TAK1 antibody [EPR5984],Abcam,AB199191
What is this antibody validated in? Alexa Fluor® 488 Anti-TAK1 antibody [EPR5984] (ab199191) is a rabbit recombinant monoclonal antibody and is validated for use in Immunocytochemistry/immunofluorescence (ICC/IF) in Mouse samples. Related products Antibody clone EPR5984 is also available pre-conjugated to a variety of labels for your convenience – Anti-TAK1 Alexa Fluor® 488 [EPR5984] (ab199191). Other related products We have a range of other formats of antibody clone [EPR5984] also available for your convenience: ab109526 , Alexa Fluor® 488 - ab199191, Carrier free - ab222394 Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Alexa Fluor® is a registered trademark of Molecular Probes, Inc, a Thermo Fisher Scientific Company. The Alexa Fluor® dye included in this product is provided under an intellectual property license from Life Technologies Corporation. As this product contains the Alexa Fluor® dye, the purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). As this product contains the Alexa Fluor® dye the sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: in manufacturing; (ii) to provide a service, information, or data in return for payment (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are sold for use in research. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or [email protected].
Host
Rabbit
Reactivity
Mouse, Human, Mouse, Rat
Application
Flow Cyt (Intra), ICC/IF, IHC-P
Conjugate
Alexa Fluor® 488
Platform ID
BAB973923081
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway (PubMed : 10094049, PubMed : 11460167, PubMed : 12589052, PubMed : 16845370, PubMed : 16893890, PubMed : 21512573, PubMed : 8663074, PubMed : 9079627). Plays an important role in the cascades of cellular responses evoked by changes in the environment (PubMed : 10094049, PubMed : 11460167, PubMed : 12589052, PubMed : 16845370, PubMed : 16893890, PubMed : 21512573, PubMed : 8663074, PubMed : 9079627). Mediates signal transduction of TRAF6, various cytokines including interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors like BMP2 and BMP4, toll-like receptors (TLR), tumor necrosis factor receptor CD40 and B-cell receptor (BCR) (PubMed : 16893890, PubMed : 9079627). Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade and the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases like MAP2K1/MEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7 (PubMed : 11460167, PubMed : 8663074). These MAP2Ks in turn activate p38 MAPKs and c-jun N-terminal kinases (JNKs); both p38 MAPK and JNK pathways control the transcription factors activator protein-1 (AP-1) (PubMed : 11460167, PubMed : 12589052, PubMed : 8663074). Independently of MAP2Ks and p38 MAPKs, acts as a key activator of NF-kappa-B by promoting activation of the I-kappa-B-kinase (IKK) core complex (PubMed : 12589052, PubMed : 8663074). Mechanistically, recruited to polyubiquitin chains of RIPK2 and IKBKG/NEMO via TAB2/MAP3K7IP2 and TAB3/MAP3K7IP3, and catalyzes phosphorylation and activation of IKBKB/IKKB component of the IKK complex, leading to NF-kappa-B activation (PubMed : 10094049, PubMed : 11460167). In osmotic stress signaling, plays a major role in the activation of MAPK8/JNK1, but not that of NF-kappa-B (PubMed : 16893890). Promotes TRIM5 capsid-specific restriction activity (PubMed : 21512573). Phosphorylates RIPK1 at 'Ser-321' which positively regulates RIPK1 interaction with RIPK3 to promote necroptosis but negatively regulates RIPK1 kinase activity and its interaction with FADD to mediate apoptosis (By similarity). Phosphorylates STING1 in response to cGAMP-activation, promoting association between STEEP1 and STING1 and STING1 translocation to COPII vesicles (PubMed : 37832545). See full target information MAP3K7
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.